Abstract:Lung cancer has evidently drawn great attention from a variety of experts from many clinical related specialties in recent years including those in health administration departments. As is already known, non-small cell lung cancer (NSCLC) is predominant, accounting for approximately 85% of all lung cancers.1 It is a global concern and is the first cause of cancer-related death among males, and second among females. Unfortunately, the majority of patients with lung cancer are diagnosed at a progressive stage when surgical treatment is urgently required.2 In China, we are also faced with increasing lung cancer morbidity and ensuring patients receive surgical treatment in a timely manner via novel management. According to the eighth edition of the TNM lung cancer stage classification revealed in 2017,3 five-year survival rate declines dramatically both clinically and pathologically in patients diagnosed with stage I to stage IV. It is therefore crucially important to intervene scientifically at an early stage, which is also reflected in the eighth edition TNM lung cancer stage classification where stage I has been divided into four subtypes. This also provides a cost-effective suggestion for clinicians and administrators. The significant findings of the study are the high cost of surgery which make the early stages of the disease no less expensive than the advanced stages on a one-year timeline after disease has first been clinically suspected.4 We agree with these findings as for operable lung cancer patients on a one-year timeline, most of this period is spent on diagnostic auxiliary examination, surgery and short-term recovery which take most time and money, and subsequent neoadjuvant chemotherapy or other treatment costs are relatively lower. For those patients in which lung cancer is determined to be inoperable, most choose treatment covered by social medical insurance at our hospital, and the most expensive small-molecule target anticancer drugs are not included. Systematic lung cancer treatment is a long journey for both patient and clinician, and we are of the view that the sooner the patient receives surgical treatment once diagnosed the better, and it is still the most cost-effective way in the whole process. Nowadays, we are faced with a contradiction between soaring medical and increasing medical needs in China. Patients want to receive medical treatment as soon as possible in order to achieve the best possible outcome. Video-assisted thoracoscopic surgery (VATS) for early-stage lung cancer patients in the Day Surgery Center at our hospital is a case in point which solves this problem, as patients usually spend less than 24 hours in hospital. An effective day surgery program is a way to recover elective surgery, especially in the era of Covid-19. It greatly reduces waiting time and hospital infection, has no severe complication or surgically-related death, as previously reported in over 177 cases in our Day Surgery Center. The average surgery cost is 34 904 RMB which is about 15% less than traditional surgery, and does not include indirect costs. We are very interested in the results of this study because it gives us solid evidence for reference in our daily practice. Although it has limitations, it still has significant meaning for clinicians and policy makers. We greatly appreciate the assistance of the staff of the Day Surgery Center, West China Hospital, Sichuan University, and thank them for their efforts. No authors report any conflict of interest.

Huge Heterogeneity Of Patient Characteristics, Treatment Patterns, Hospital Costs Exists In Non-Small Cell Lung Cancer Surgeries Among Different Centers Of China: A Study Of 5060 Patients Based On The Chinese National Nsclc Outcome Registry.

P1.01-046 Heterogeneity of NSCLC Surgery Exists in Treatment Patterns and Hospital Costs among Different Centers of China, a Study of 5060 Patients: Topic: Prognostic Factors, Treatment

Surgical Treatments of Chinese Patients with Lung Malignant Tumors.

Real-world Surgical Treatment Patterns and Clinical Outcomes in Patients with Stages IA–IIIA Non-Small Cell Lung Cancer: a Retrospective Multicentric Observational Study Involving 11,958 Patients

The Cross-Sectional Study of Chinese Non-Small Cell Lung Cancer Surgical Treatment Patterns in 2013-2014

A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

Comparison of Surgeries Plus Perioperative and Postoperative Chemotherapies in Chinese Pn2 Patients with Non-Small Cell Lung Cancer: A Real-World Observational Study.

Lymph node metastasis in Chinese patients with clinical T1 non-small cell lung cancer: A multicenter real-world observational study.

Preoperative Lymph Node Assessment in Surgically Resected Pathologic T1 Lung Cancer Patients: Real World Clinical Practice in China.

Risk Analyses of N2 Lymph-Node Metastases in Patients with T1 Non-Small Cell Lung Cancer: a Multi-Center Real-World Observational Study in China

Outcomes and Prognosis of Non-Small Cell Lung Cancer Patients Who Underwent Curable Surgery: a Protocol for a Real-World, Retrospective, Population-Based and Nationwide Chinese National Lung Cancer Cohort (CNLCC) Study

Effectiveness and Safety of Systematic and Selective Lymphadenectomies in Chinese Patients with Non-Small Cell Lung Cancer Who Received Sublobar Resection.

Ten-year trends of the clinicopathological characteristics, surgical treatments and survival outcomes of operable lung cancer patients in monocenter: a retrospective cohort study

Comparison of Clinical Characteristics and Prognoses of Patients with T1 Non-Small Cell Lung Cancer and Small Cell Lung Cancer in a Chinese Real-World Study.

Chinese Multi-Institutional Registry (Cmir) For Resected Non-Small Cell Lung Cancer: Survival Analysis Of 5,853 Cases

Response To: Estimated Direct Costs of Non‐small Cell Lung Cancer by Stage at Diagnosis and Disease Management Phase: A Whole‐disease Model

Treatment Patterns, Clinical Outcomes, and Healthcare Resource Use Associated with Advanced/metastatic Lung Cancer in China: Protocol for a Retrospective Observational Study

Real-world Clinical Characteristics and Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Patients in China.

Clinic Information, Pathological, and Imaging Characteristics in 2 058 Surgical Patients with Lung Cancer from a Single Center.

Survival of 7,311 Lung Cancer Patients by Pathological Stage and Histological Classification: a Multicenter Hospital-Based Study in China

The Cost Of Treating Advanced Non-Small Cell Lung Cancer: Estimates From The Chinese Experience